Nursing Review March-April 2016 | Page 23

clinical practice The GP thought: “Everything seems normal, you seem fit, but I’m just going to check your tummy.” He thought he felt an aneurysm there so he sent him off for an ultrasound. There was no aneurysm there, but it looked like there was something funny with the pancreas, so he sent him off for a CT scan of the pancreas. That was normal, but they spotted something on the liver. So they said: “Oh, we have to biopsy that because it looks like it might be a tumour,” So they biopsied it. It turned out to be a congenital hemangioma, which is a vascular abnormality of the liver. It was harmless, except if you put a needle in it. He bled severely and he could have died. He spent several weeks in hospital as a result of this, all from a series of tests that were to do with nothing. Now that’s an extreme example but that sort of thing is happening all the time with those thyroid incidentalomas I was talking about. People are now having thyroid surgery and getting the complications from it. You can get local infections afterwards. You can also get a nerve problem that causes you to lose your voice from it. That’s probably the most serious one. If we keep doing more of these, it can get worse. To give you an extreme case from South Korea, there has been an almost 20-fold increase in the number of thyroid cancers recorded there because they’re doing so much use of ultrasound to look. The three-fold increase in Australia is small compared with that, but if we kept going the way of South Korea, we could end up there as well. This is occurring in the whole body, with all sorts of things and with all sorts of tests that we do. The tests are good, but we have to learn to use them more wisely in order to avoid all of these downsides. It’s not just a cost problem. It’s this follow-on problem of the sequence of testing and complications and labelling that occurs with people we’re concerned about. This is a five-year project starting in January 2017. Over those five years, what would success look like? There are two things we need to do. One is that we need a better understanding of this problem. This has been an under-recognised and under-researched problem. The second is we then need ways of intervening with that problem to reduce the dangers of the tests, while keeping the advantages of the tests, so there’s this fine balance we need to work out. For example, we don’t know the exact pathways by which those excessive thyroid nodules, I’ll call them, are being detected. So we need to check what the medical records are, talk to people who’ve had the cases, etc, to find out what was the pathway, how this happened and what they were being investigated for, to have a better understanding of that. Based on anecdotes, we think much of it’s due to the ultrasounds being done on the neck arteries, and then the ultrasonographers just having a look. But we don’t know all the pathways and how common they are – we need absolute understanding. Then, we want to do a whole lot of intervention studies. For example, one of the things we want to try for imaging of the lower back to analyse back pain is to use what’s called delayed imaging. We know that delayed prescribing is effective for the doubtful cases of antibiotic usage, but nobody’s tried it for imaging. [With] imaging of the back early on in acute back pain, unless there’s what’s called a red flag – something that tells you there might be something seriously wrong like a tumour or an infection or something – we’ve got very, very good data to say that imaging does not help and that it can lead to harm. Despite that, lots of people get x-rays, MRIs and CT scans done early on [when experiencing] back pain. Partly, that’s due to the expectations of patients who feel like they want to know what’s going on; that expectation comes through to the doctors who order it as well. By using delayed imaging, we say [in effect] most people will be getting better in a couple of weeks, but if you’re not, then you can go and get this imaging. We expect that will roughly halve the rate of imaging and, therefore, stop a lot of the incidentalomas being detected. Further down the track, we want to use shared decision-making for patients. When results come back, there’s a dilemma about whether you should treat for some cases. Patients and doctors have quite false expectations about what the benefits of some treatments are. If we inform particularly the patients about the benefits and harms of some of the treatments, we think we can better guide the patients who will benefit to get treatment and those who won’t benefit so much not to get the treatments. what are the risks of taking no action with regard to the spread of incidentalomas? We think this is addressing probably the most important problem in the future of medicine. Because our technology keeps improving all the time, but there’s always a downside to that technology and we’ve got to work out how to optimise the benefits and harms from it. Otherwise, we think this is a genuine threat to the sustainability of medicine. Most of the increases occurring in the cost of medicine and the harms of medicine are due to us not finding that correct balance at the moment. This is vital work to be done now, so we’re looking forward to getting on with it. n Lecturer/Senior Lecturer/Associate Professor Applications are invited f ܈HX